Loading...
The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer
Trastuzumab, an anti-ErbB2 humanized antibody, brings benefit to patients with ErbB2-amplified metastatic breast cancers. However, the resistance to trastuzumab is common. Our previously reported H2-18, an anti-ErbB2 antibody, potently induced programmed cell death in trastuzumab-resistant breast ca...
Na minha lista:
| Udgivet i: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Impact Journals LLC
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5581078/ https://ncbi.nlm.nih.gov/pubmed/28881779 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17907 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|